A single CD19 CAR-T infusion held three of six refractory rheumatoid arthritis patients drug-free

The trial is testing whether CD19 CAR-T cells can rebuild the B-cell system, not just suppress it more strongly. The Charite group's argument is that CD19 CAR-T cells can hit the B cells keeping the disease persistent, clear the pathological B-cell memory, and let the B-cell system start fresh ^[21]. The corroborating measurement is the sharp decline in the autoantibodies characteristic of RA after infusion ^[11], which is what you would expect if the compartment producing them had been emptied. But that decline shows depletion, not durability: a titre can fall and the memory that regenerates it can come back.

Six is the denominator. The endpoint structure matters more than the remission count. The primary endpoints were the incidence and severity of cytokine release syndrome, ICANS and adverse events in the first four weeks ^[10], which makes every efficacy figure in this trial a secondary or exploratory reading ^[19]. There was no comparator arm; comparison arrives only in the second phase ^[20]. Three of six, half the cohort, were off all RA medication at last follow-up ^[6][15]. Read alongside the single patient whose disease returned after an initial medication-free period ^[13], that implies at least four of the six reached a drug-free interval and one did not keep it ^[17]. Follow-up ran 36 to 52 weeks ^[5], roughly eight months to a year ^[16], against a disease that otherwise requires lifelong medication ^[9].

The second phase is the more informative experiment. Ten additional patients, and the comparator is a drug already approved for RA that also depletes B cells ^[14]. That controls the obvious confound, because anything that removes B cells will help RA for a while; the live question is whether a one-time reset beats continuing depletion on depth and duration, which is precisely what the investigators say they are testing ^[14]. Sixteen patients across both phases ^[18] are enough to test whether "reset" is a mechanism or a label, not enough to tell anyone who should get this.

What rheumatology would inherit, if the effect holds up, is an oncology workflow. The product is autologous ^[3], so every dose is a manufacturing run for one person. Patients stopped all disease-modifying antirheumatic drugs and received standard lymphodepletion before the infusion ^[5]. All six developed CRS, temporary and mild to moderate, reported as readily manageable, with no severe neurological complications and rare infections ^[12]. That record was produced at Charite's Hematology Early Clinical Trial Unit, whose medical director, Marie Luise Huetter-Kroenke, described it ^[12]. How a unit that sees this kind of CRS only a few times a year, rather than most weeks, would manage it is a separate question this record cannot answer. The washout carries its own exposure: a patient off all DMARDs and through lymphodepletion needs somewhere to go if the reset does not take, and there is no long-term experience with this therapy to draw on ^[5][7].

Gerhard Kroenke, who leads the joint clinical rheumatology group at Charite and the German Rheumatology Research Center ^[8], keeps the framing narrow, and it is worth keeping it there: selected patients who have not responded adequately to existing treatment, in whom it may in future be possible to reset immune memory rather than suppress inflammation continuously ^[22].